Patent · US Active

Compositions, methods and uses for treating solid tumors using LCMV-GP-VSV pseudotype vectors

US10265357B2 · kind B2 · utility

3Cited by

0References

23Claims

0Family size

Assignee

ViraTherapeutics GmbH · AT

Inventors

Dorothee Von Laer · Innsbruck, AT
Tsanan Heimann · Mainz, DE

Key dates

Filing date	Jun 16, 2014
Grant date	Apr 23, 2019
Priority date	—
Expiry date	Oct 12, 2034

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2810/6072
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Embodiments of the present invention relate to compositions and methods for producing recombinant VSV viruses. In accordance with these embodiments, viral vectors can include a glycoprotein GP of the lymphocyte choriomeningitis virus (LCMV) instead of the G protein of the VSV. Other embodiments relate to cells for producing a LCMV-GP-pseudotyped VSV vectors. Embodiments also relate to the use of the vectors and cells as part of a pharmaceutical composition for the treatment of solid tumors.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.